KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Receivables: 2010-2016

Historic Change in Receivables for Novavax (NVAX) over the last 6 years, with Dec 2016 value amounting to -$356,000.

  • Novavax's Change in Receivables rose 82.31% to -$356,000 in Q4 2016 from the same period last year, while for Dec 2016 it was -$2.1 million, marking a year-over-year increase of 75.56%. This contributed to the annual value of -$144.4 million for FY2021, which is 41.25% up from last year.
  • As of Q4 2016, Novavax's Change in Receivables stood at -$356,000, which was down 250.85% from $236,000 recorded in Q3 2016.
  • In the past 5 years, Novavax's Change in Receivables ranged from a high of $2.8 million in Q4 2014 and a low of -$6.0 million during Q2 2015.
  • In the last 3 years, Novavax's Change in Receivables had a median value of -$428,000 in 2015 and averaged -$561,167.
  • As far as peak fluctuations go, Novavax's Change in Receivables soared by 1,661.25% in 2014, and later crashed by 2,569.23% in 2016.
  • Quarterly analysis of 5 years shows Novavax's Change in Receivables stood at -$1.5 million in 2012, then skyrocketed by 110.97% to $160,000 in 2013, then skyrocketed by 1,661.25% to $2.8 million in 2014, then slumped by 171.43% to -$2.0 million in 2015, then surged by 82.31% to -$356,000 in 2016.
  • Its last three reported values are -$356,000 in Q4 2016, $236,000 for Q3 2016, and -$26,000 during Q2 2016.